RxDoctor Payments Data

Subodh Adhikari, MD

Hospitalist · Hattiesburg, MSNPI 1457731861

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.1% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Medtronic at 52.8% of the total. Reporting peaked in 2024 at $849 and has fallen 97.9% since, to $18 in 2025.

$1,429in general payments, 2019–2025

Across 47 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$755
  • AbbVie$153
  • E.r. Squibb & Sons, L.L.C.$117
  • AstraZeneca$101
  • Johnson & Johnson$91
  • Boehringer Ingelheim$72
  • plus $141 from 3 others

What the payments were for

  • Food & beverage$1,34494%
  • Education$856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 75th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$74,664
Medicare patients
243
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$22,073
LinzessLinaclotide21$5,337
Cefdinir27$268
Metoprolol Succinate19$221
Atorvastatin Calcium22$184
ClopidogrelClopidogrel Bisulfate18$160
Pantoprazole Sodium27$159
Furosemide27$157
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$150
Rosuvastatin Calcium13$118
Amlodipine Besylate21$100
Prednisone17$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$22,07333 claims
AbbVieLinzess$153$5,33721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →